Analyst Consensus ?
ConsensusHold43 ratings
Bullish1637.2%
Neutral2558.1%
Bearish24.7%
Universal Health Services, Inc. · UHS · FY2024 Q2 · Calendar Q3 2024
UHS raises outlook as behavioral health and cost controls lead
The quarter supports a constructive operating trajectory, led by behavioral health, improving labor execution, and reimbursement opportunities; the key test is whether these drivers can offset moderating acute-care trends and policy dependence.
Reported After market closeNYSEHealthcare
$10.95B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$4.31
Consensus $3.28
EPS surprise
+31.4%
Reported versus consensus
Reported revenue
$3.91B
Consensus $3.87B
Revenue surprise
+1.1%
Reported versus consensus
Market reaction
event-close to next-session close
Stock move
+10.2%
Event window
SPY move
-0.5%
Same window
Abnormal move
+10.7%
Stock minus SPY
Volume
3.8×
Versus trailing sessions
Subsequent drift
+11.9%
Up to 20 sessions
UHSSPY benchmark
Ask FN2 about UHS FY2024 Q2
Transcript, numbers and history already loaded
Why did UHS rise 10.2% after beating EPS estimates in FY2024 Q2?What changed in UHS's guidance and outlook in FY2024 Q2?Give me the bull and bear case for UHS after FY2024 Q2 earnings.
Free account. Your question opens in FN2 with this report's transcript and numbers attached.
Transcript intelligence
What changed
The current quarter showed a raised outlook and a more defined contribution from behavioral health, staffing improvements, new facilities, and Medicaid supplemental-payment opportunities, while acute-care growth remained a central question.
Guidance delta
Management raised full-year earnings guidance, supported by behavioral-health strength, cost control, and expected contributions from new facilities and supplemental-payment programs.
Key takeaways
- Behavioral health remained the clearest growth engine, while acute-care demand was more moderate.
- Management highlighted better staffing trends, lower turnover, and reduced reliance on premium pay.
- The outlook depends in part on new facilities and pending or expanding Medicaid supplemental-payment programs.
Management priorities
- Expand acute-care, behavioral-health, and freestanding emergency capacity.
- Advance state Medicaid supplemental-payment opportunities and related approvals.
- Maintain labor-cost discipline while continuing capital returns and facility development.
Follow UHS with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$185.71Previous close
$121Low
$190.12Average
$290High
Latest persisted target per named analyst; persisted previous close from FN2's market snapshot as of Oct 27, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Leerink Partners | Outperform | Outperform | Maintain | Sep 18, 2026 |
| RBC Capital | Sector Perform | Sector Perform | Maintain | Aug 20, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jul 30, 2026 |
| Morgan Stanley | Equal Weight | Equal Weight | Maintain | Jul 29, 2026 |
| Guggenheim | Buy | Buy | Maintain | Jul 29, 2026 |
| Cantor Fitzgerald | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Baird | Neutral | Neutral | Maintain | Jul 29, 2026 |
| Barclays | Equal Weight | Equal Weight | Maintain | Jul 28, 2026 |
| Wells Fargo | Equal Weight | Equal Weight | Maintain | Jul 13, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jun 22, 2026 |
| UBS | Buy | Buy | Maintain | Apr 30, 2026 |
| JP Morgan | Neutral | Neutral | Maintain | Aug 4, 2025 |
| B of A Securities | Underperform | Neutral | Downgrade | Jul 16, 2025 |
| Stephens & Co. | Equal Weight | Equal Weight | Maintain | Feb 28, 2025 |
| Deutsche Bank | Buy | Buy | Maintain | Apr 12, 2024 |
| Mizuho | Buy | Buy | Maintain | Mar 6, 2024 |
| Citigroup | Buy | Buy | Maintain | Feb 29, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | Jul 27, 2023 |
| SVB Securities | Outperform | Market Perform | Upgrade | May 26, 2023 |
| Wolfe Research | Peer Perform | Outperform | Downgrade | Mar 1, 2023 |
| SVB Leerink | Market Perform | Market Perform | Maintain | Oct 27, 2022 |
| BMO Capital | Underperform | Market Perform | Downgrade | Jul 6, 2022 |
| Loop Capital | Hold | Hold | Maintain | Jun 17, 2022 |
| Seaport Global | Neutral | Buy | Downgrade | Feb 28, 2022 |
| Piper Sandler | Neutral | Neutral | Maintain | Feb 28, 2022 |
| Bank of America | Buy | Neutral | Upgrade | Sep 18, 2018 |
| PiperJaffray | Neutral | Overweight | Downgrade | Jan 3, 2018 |
| Leerink Swann | Outperform | Outperform | Maintain | Sep 22, 2017 |
| Raymond James | Market Perform | Outperform | Downgrade | Dec 14, 2016 |
| Avondale Partners | Market Perform | Market Outperform | Downgrade | Nov 9, 2016 |
| Wallachbeth | Hold | Buy | Downgrade | Oct 11, 2016 |
| Sterne Agee CRT | Neutral | Underperform | Upgrade | Mar 2, 2016 |
| Sterne Agee | Neutral | Underperform | Upgrade | Mar 2, 2016 |
| Standpoint Research | Buy | Hold | Upgrade | Feb 10, 2016 |
| KeyBanc | Overweight | Sector Weight | Upgrade | Oct 1, 2015 |
| Janney Capital | Neutral | Neutral | Maintain | Jun 10, 2015 |
| FBR Capital | Outperform | Outperform | Maintain | Apr 28, 2014 |
| Monness Crespi Hardt | Neutral | Neutral | Maintain | Mar 31, 2014 |
| Susquehanna | Neutral | Positive | Downgrade | May 17, 2013 |
| WallachBeth Capital | Hold | Buy | Downgrade | Mar 4, 2013 |
| Imperial Capital | Outperform | Outperform | Maintain | Sep 13, 2012 |
| Jefferies | Hold | Hold | Maintain | Apr 27, 2012 |
| Auriga | Buy | Buy | Maintain | Feb 28, 2012 |
Named analyst price targets
Upside is calculated against the persisted previous close $185.71. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| RBC Capital | Ben Hendrix | $183 | $171.8 | -1.5% | Aug 3, 2026 |
| Goldman Sachs | Analyst unavailable | $190 | $168.16 | +2.3% | Jul 30, 2026 |
| UBS | Analyst unavailable | $290 | $166.22 | +56.2% | Jul 29, 2026 |
| Guggenheim | Jason Cassorla | $189 | $166.22 | +1.8% | Jul 29, 2026 |
| Robert W. Baird | Analyst unavailable | $166 | $166.22 | -10.6% | Jul 29, 2026 |
| Morgan Stanley | Craig Hettenbach | $191 | $166.22 | +2.8% | Jul 29, 2026 |
| Barclays | Analyst unavailable | $168 | $159.31 | -9.5% | Jul 28, 2026 |
| Guggenheim | Analyst unavailable | $195 | $151.16 | +5.0% | Jul 20, 2026 |
| Wells Fargo | Analyst unavailable | $166 | $155.57 | -10.6% | Jul 13, 2026 |
| Barclays | Analyst unavailable | $179 | $161.26 | -3.6% | Jul 8, 2026 |
| Wells Fargo | Analyst unavailable | $165 | $146.11 | -11.2% | Jun 1, 2026 |
| UBS | Analyst unavailable | $310 | $167.86 | +66.9% | Apr 30, 2026 |
| Cantor Fitzgerald | Analyst unavailable | $194 | $167.51 | +4.5% | Apr 29, 2026 |
| RBC Capital | Analyst unavailable | $190 | $162.54 | +2.3% | Apr 29, 2026 |
| Guggenheim | Analyst unavailable | $211 | $162.54 | +13.6% | Apr 29, 2026 |
| Robert W. Baird | Michael Ha | $204 | $162.54 | +9.8% | Apr 29, 2026 |
| Barclays | Analyst unavailable | $238 | $179.51 | +28.2% | Apr 28, 2026 |
| Barclays | Analyst unavailable | $262 | $203.68 | +41.1% | Jan 22, 2026 |
| UBS | Analyst unavailable | $245 | $214.97 | +31.9% | Jan 7, 2026 |
| Wells Fargo | Analyst unavailable | $235 | $221.74 | +26.5% | Jan 7, 2026 |
| Guggenheim | Jason Cassorla | $274 | $239.43 | +47.5% | Dec 2, 2025 |
| Raymond James | John Ransom | $270 | $217.01 | +45.4% | Nov 3, 2025 |
| UBS | Analyst unavailable | $231 | $225.3 | +24.4% | Oct 30, 2025 |
| RBC Capital | Ben Hendrix | $231 | $223.61 | +24.4% | Oct 30, 2025 |
| UBS | Analyst unavailable | $302 | $219.32 | +62.6% | Oct 29, 2025 |
| Guggenheim | Jason Cassorla | $253 | $219.32 | +36.2% | Oct 29, 2025 |
| Morgan Stanley | Craig Hettenbach | $233 | $219.32 | +25.5% | Oct 29, 2025 |
| Barclays | Analyst unavailable | $263 | $214.03 | +41.6% | Oct 28, 2025 |
| Mizuho Securities | Ann Hynes | $242 | $214.03 | +30.3% | Oct 28, 2025 |
| Goldman Sachs | Analyst unavailable | $219 | $197.76 | +17.9% | Oct 14, 2025 |
| Wells Fargo | Analyst unavailable | $249 | $209.11 | +34.1% | Oct 7, 2025 |
| Robert W. Baird | Michael Ha | $203 | $177.91 | +9.3% | Aug 14, 2025 |
| UBS | Analyst unavailable | $227 | $165.44 | +22.2% | Jul 30, 2025 |
| Morgan Stanley | Analyst unavailable | $200 | $184.46 | +7.7% | Mar 26, 2025 |
| Robert W. Baird | Michael Ha | $274 | $236.47 | +47.5% | Sep 4, 2024 |
| Raymond James | Sarah James | $219 | $204.99 | +17.9% | Jul 26, 2024 |
| Barclays | Andrew Mok | $256 | $210.68 | +37.8% | Jul 26, 2024 |
| Robert W. Baird | Michael Ha | $236 | $187.7 | +27.1% | Jun 26, 2024 |
| HSBC | Sidharth Sahoo | $290 | $94 | +56.2% | Jun 5, 2024 |
| UBS | AJ Rice | $226 | $177.7 | +21.7% | May 20, 2024 |
| RBC Capital | Frank Morgan | $189 | $169.15 | +1.8% | May 7, 2024 |
| Deutsche Bank | Pito Chickering | $203 | $168.4 | +9.3% | Apr 12, 2024 |
| Stephens | Scott Fidel | $185 | $182.46 | -0.4% | Apr 1, 2024 |
| Barclays | Steven Valiquette | $142 | $140.7 | -23.5% | Apr 25, 2023 |
| Barclays | Analyst unavailable | $132 | $152.21 | -28.9% | Jan 9, 2023 |
| Wells Fargo | Stephen Baxter | $154 | $142.04 | -17.1% | Jan 3, 2023 |
| Goldman Sachs | Analyst unavailable | $110 | $102.03 | -40.8% | Jul 12, 2022 |
| Credit Suisse | Analyst unavailable | $141 | $102.24 | -24.1% | Jul 1, 2022 |
| Mizuho Securities | Analyst unavailable | $121 | $102.07 | -34.8% | Jul 1, 2022 |
| Mizuho Securities | Analyst unavailable | $153 | $124.98 | -17.6% | May 3, 2022 |
| Wells Fargo | Analyst unavailable | $118 | $124.16 | -36.5% | Apr 28, 2022 |
| Stephens | Analyst unavailable | $135 | $124.32 | -27.3% | Apr 27, 2022 |
| Credit Suisse | Analyst unavailable | $158 | $125.32 | -14.9% | Apr 27, 2022 |
| RBC Capital | Analyst unavailable | $130 | $125.32 | -30.0% | Apr 27, 2022 |
| Mizuho Securities | Ann Hynes | $145 | $69.38 | -21.9% | Apr 26, 2022 |
| Goldman Sachs | Jamie Perse | $135 | $128.04 | -27.3% | Nov 9, 2021 |
| Stephens | Scott Fidel | $142 | $124.54 | -23.5% | Oct 27, 2021 |
| BMO Capital | Matthew Borsch | $145 | $124.54 | -21.9% | Oct 27, 2021 |
| Bank of America Securities | Kevin Fischbeck | $153 | $125.79 | -17.6% | Oct 26, 2021 |
| Credit Suisse | A.J. Rice | $181 | $158.43 | -2.5% | Jul 27, 2021 |
| Wolfe Research | Justin Lake | $171 | $151.2 | -7.9% | Jun 21, 2021 |
Track every rating change on UHS the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationUniversal Health Services, Inc. (UHS), operating through its various divisions, is a healthcare entity that both owns and manages a network of acute care hospitals, along with outpatient and specialized behavioral health treatment centers. Its business operations are strategically bifurcated into two main segments: Acute Care Hospital Services and Behavioral Health Care Services. The hospitals under its management provide a comprehensive spectrum of medical provisions, encompassing general and specialty surgical interventions, internal medicine, obstetrics, urgent and emergency department services, diagnostic imaging (radiology), cancer therapy (oncology), advanced diagnostic procedures, cardiac care, pediatric medicine, pharmaceutical services, and mental health support.…
Historical context
All UHS earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| RDY Dr. Reddy's Laboratories Limited | FY2027 Q2 · Calendar Q4 2026 | +24.0% | -0.2% | Dr. Reddy’s: margins improve as semaglutide rollout advances |
| DGX Quest Diagnostics Incorporated | FY2026 Q3 · Calendar Q4 2026 | +4.5% | +1.8% | Quest Diagnostics: growth broadens, but PAMA remains a headwind |
| ARGX argenx SE | FY2026 Q3 · Calendar Q4 2026 | — | -1.6% | argenx: VYVGART momentum and a broader late-stage pipeline |
| MEDP Medpace Holdings, Inc. | FY2026 Q3 · Calendar Q4 2026 | +9.0% | -1.3% | Medpace: Record awards lift backlog as 2026 outlook improves |
Latest beats and misses
Who reports nextBeat on EPS
- VZFY2026 Q3 · October 26, 2026+3.1% EPS-3.5% move
- CXFY2026 Q3 · October 26, 2026+12.0% EPS-0.1% move
- CDNSFY2026 Q3 · October 26, 2026+2.9% EPS+1.8% move
- BAHFY2027 Q2 · October 23, 2026+18.9% EPS-0.3% move
- FCNCAFY2026 Q3 · October 23, 2026+19.9% EPS+8.2% move
- FCNCNFY2026 Q3 · October 23, 2026+19.9% EPS+0.2% move
Missed on EPS
- KOFFY2026 Q3 · October 26, 2026-9.0% EPS-1.9% move
- INFYFY2027 Q2 · October 23, 2026-4.8% EPS-6.6% move
- BBDFY2026 Q3 · October 22, 2026-7.7% EPS+3.0% move
- SNAFY2026 Q3 · October 22, 2026-5.9% EPS-3.4% move
- SPOTFY2026 Q3 · October 22, 2026-11.6% EPS+11.1% move
- VRSNFY2026 Q3 · October 22, 2026-2.0% EPS-0.9% move
Get the UHS recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2024-10-17T05:10:49.140638+00:00
- Polygon adjusted daily market bars · 2026-10-27T07:00:43.292179+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-10-27T07:00:43.289206+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-10-27. For educational purposes only; not investment advice.